🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver

RecruitingPhase 4Ages 18 Years - anyMaleBangladesh Medical University
NCT07816094 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a prospective, randomized, open-label clinical trial designed to compare the antiviral efficacy and safety of entecavir 0.5 mg once daily versus entecavir 1.0 mg once daily in adult patients with hepatitis B virus (HBV)-related decompensated liver cirrhosis. A total of 48 participants will be randomized equally to the two treatment groups and followed for 24 weeks. The primary outcome is the reduction in serum HBV DNA at week 24. Secondary outcomes include changes in Child-Pugh and MELD scores, HBeAg seroconversion, development or worsening of hepatic decompensation, occurrence of hepatocellular carcinoma, and safety of treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age: 18 years or older. 2. HBV-related decompensated cirrhosis of liver based on clinical, biochemical and radiological evidence. 3. Detectable level of HBV DNA irrespective of HBeAg status. Exclusion Criteria: 1. Clinical, biochemical, or radiological evidence of hepatocellular carcinoma. 2. Coinfection with HCV. 3. Patient is ongoing antiviral treatment. 4. Cirrhosis due to other causes. 5. Acute-on-chronic liver failure, defined according to the criteria established by APASL. 6. Pregnancy. 7. Patients with known hypersensitivity or allergy to Entecavir.
💊

What it tests

  • Entecavir
📍

Where

1 site
Bangladesh Medical university
Dhaka, Bangladesh
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy